Related Experiment Video
Updated: Dec 20, 2025
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
Latest progress in molecular biology and treatment in genitourinary tumours
A González-Del-Alba1, J Á Arranz2, J Bellmunt3
1Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
Abstract:
The management of genitourinary cancer, including bladder, prostate, renal and testicular cancer, has evolved dramatically in recent years due to a better understanding of tumour genetic mutations, alterations in molecular pathways, and to the development of new kinds of drugs such as targeted therapies and immunotherapies. In the field of immunotherapy, new drugs focused on stimulating, enhancing and modulating the immune system to detect and destroy cancer, have been recently discovered. Research in oncology moves quickly and new data of great relevance for clinical practice are communicated every year. For this reason, a group of experts, focused exclusively on the treatment of genitourinary tumours and who get together every year in the BestGU conference to assess the latest progress in this field have summarized the most important advances in a single review, along with a critical assessment of whether these results should alter daily clinical practice.
Insights
Recent advances in genitourinary cancer treatment, including targeted therapies and immunotherapies, offer new hope. Experts critically assess these breakthroughs to guide clinical practice for bladder, prostate, renal, and testicular cancers.
Area of Science:
- Oncology
- Genitourinary Cancer Research
Background:
- Genitourinary cancer management has rapidly advanced due to insights into tumor genetics and molecular pathways.
- Development of novel therapeutics, including targeted therapies and immunotherapies, has transformed treatment paradigms.
Purpose of the Study:
- To review and critically assess the most significant recent advances in genitourinary cancer treatment.
- To provide expert guidance on whether new findings should alter daily clinical practice.
Main Methods:
- Expert consensus and critical review of the latest research presented at the BestGU conference.
- Focus on advancements in targeted therapies and immunotherapies for genitourinary malignancies.
Main Results:
- Significant progress in understanding tumor genetics and molecular pathways.
- Emergence of novel immunotherapies and targeted drugs for bladder, prostate, renal, and testicular cancers.
- Identification of key findings with potential to impact clinical decision-making.
Conclusions:
- The field of genitourinary oncology is rapidly evolving with promising new therapeutic options.
- Expert evaluation is crucial to integrate these advances into routine clinical practice effectively.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
01:29Microorganisms in Medicine and Therapeutics